Amarin Corp Plc (AMRN)

[ilovetech]

KC_EN, to come out with this article that points to Trigs in a vacuum, with no regard to other biomarkers we've since learned are of equal importance in the prevention of CVD, is pointless and misleading. What about hs-crp levels?.. etc. To say they "can't recommend" either Lovaza or Vascepa over the other is to pretend we never had a Reduce-it study. As a matter of obligation, these doctors should be required to focus on outcomes, and not discuss a single relic, trigs, especially in the grander scheme of what we've learned since Reduce-it top line. Moreover, the article further fuels health Insurance Providers to keep Lovaza alive and well to muddy pre-authorizations for V.

ILT